GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats

Jpn J Pharmacol. 1997 Jul;74(3):285-9. doi: 10.1254/jjp.74.285.

Abstract

Effect of subchronically administered GTS-21 [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride], a selective nicotinic agonist, on neuronal cell loss caused by nucleus basalis magnocellularis (nBM) lesion was studied in rats. After 2 weeks of bilateral nBM excitotoxic lesion, GTS-21 was orally administered once daily for 20 weeks. Neuronal cell loss was observed in layers II-III of the parietal cortex in the lesioned control rats. GTS-21 significantly attenuated the neuron loss in these layers. These results suggest that GTS-21 exhibits a protective action against the neuronal cell death in the parietal cortex and may have a beneficial effect on neurodegenerative disorders such as an Alzheimer-type disease.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Benzylidene Compounds / pharmacology*
  • Cell Death
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / physiopathology
  • Male
  • Neurons / drug effects
  • Neuroprotective Agents / pharmacology*
  • Nicotine / pharmacology
  • Nicotinic Agonists / pharmacology*
  • Pyridines / pharmacology*
  • Rats
  • Rats, Wistar
  • Substantia Innominata / physiopathology*

Substances

  • Benzylidene Compounds
  • Neuroprotective Agents
  • Nicotinic Agonists
  • Pyridines
  • Nicotine
  • 3-(2,4-dimethoxybenzylidene)anabaseine